Oxford BioMedica (LSE:OXB) FCF Margin %: -6.67% (As of Dec. 2025)


LSE:OXB Oxford BioMedica PLC LSE:OXB
68 GF Score
Price £6.14
GF Value £5.36
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Oxford BioMedica FCF Margin %?

Oxford BioMedica LSE:OXB +2.33% 68 FCF Margin % is -6.67% as of Dec. 2025. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.36 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 960 Biotechnology companies, Oxford BioMedica ranks better than 73.23% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oxford BioMedica's Free Cash Flow for the six months ended in Dec. 2025 was £-6.4 Mil. Oxford BioMedica's Revenue for the six months ended in Dec. 2025 was £95.5 Mil. Therefore, Oxford BioMedica's FCF Margin % for the quarter that ended in Dec. 2025 was -6.67%.

As of today, Oxford BioMedica's current FCF Yield % is -0.57%.

The historical rank and industry rank for Oxford BioMedica's FCF Margin % or its related term are showing as below:

LSE:OXB' s FCF Margin % Range Over the Past 10 Years
Min: -45.71   Med: -16.16   Max: 11.2
Current: -2.52

During the past 13 years, the highest FCF Margin % of Oxford BioMedica was 11.20%. The lowest was -45.71%. And the median was -16.16%.

LSE:OXB's FCF Margin % is ranked better than
73.23% of 960 companies
in the Biotechnology industry
Industry Median: -85.21 vs LSE:OXB: -2.52

Oxford BioMedica FCF Margin % Related Terms

Oxford BioMedica FCF Margin % Historical Data

* Premium members only.

The historical data trend for Oxford BioMedica's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioMedica FCF Margin % Chart

Oxford BioMedica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.20 -20.65 -42.83 -45.16 -2.52

Oxford BioMedica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.42 -86.63 -18.14 2.90 -6.67

LSE:OXB vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Oxford BioMedica's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's FCF Margin % falls into.


LSE:OXB
68GF Score
Oxford BioMedica PLC LSE:OXB
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oxford BioMedica FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oxford BioMedica's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-4.254/168.741
=-2.52 %

Oxford BioMedica's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.375/95.518
=-6.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -6.67% mean?
Oxford BioMedica (LSE:OXB) has a FCF Margin % of -6.67% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxford BioMedica and its competitors. According to the industry distribution chart, Oxford BioMedica ranks #257 out of 960 companies in the Biotechnology industry, placing it in the top 26.8%.
Is Oxford BioMedica's FCF Margin % too high?
Oxford BioMedica's current FCF Margin % is -6.67%. Based on the distribution chart, Oxford BioMedica ranks #257 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #257 out of 960 companies for FCF Margin %. This puts Oxford BioMedica in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Oxford BioMedica and its competitors. Oxford BioMedica's current FCF Margin % is -6.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.36, compared to a current price of £6.14 — trading 14.6% above its estimated fair value. The current FCF Margin % is -6.67%. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current FCF Margin % is -6.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?

Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued. The current stock price of £6.14 is trading 14.6% above its estimated GF Value™ of £5.36. GuruFocus considers Oxford BioMedica to be Modestly Overvalued.

Key valuation signals for LSE:OXB:

  • FCF Margin %: -6.67%
  • GF Value™: £5.36 vs. price of £6.14 (14.6% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oxford BioMedica Business Description

Other Exchanges OXBDF:USAOXBl:UKOXO:Germany
Address Transport Way, Windrush Court, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score

Get the complete analysis for LSE:OXB

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£6.14
Price
£5.36
GF Value